-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Nano-scale secretory capsules called exosomes are released from the cell membrane to achieve multiple functions such as remodeling the tissue matrix and transmitting signals
.
Their important role in many aspects of human health and disease makes them an ideal therapeutic drug or drug delivery system for the treatment of many diseases
Capricor Therapeutics is a biotechnology company focused on the development of exosome therapies.
The company and their collaborators at the U.
S.
Army Institute of Surgery (USAISR) published a new preclinical study in which scientists explore the isolation of regenerated progenitor cells The therapeutic potential of the exosomes
.
The authors used exosomes called cardiogenic exosomes (CDC-EVs) to treat a rat model of acute traumatic coagulopathy (ATC).
ATC is the blood clotting in the circulation caused by trauma
.
The results of this study were published in the Journal of Trauma and Acute Care Surgery, entitled "Myocardial extracellular vesicles as a potential anti-shock therapy
The first task in allowing cdc-ev to be used in the treatment of ATC is to prove that they themselves do not promote blood clotting during injection
.
To confirm this, the authors used flow cytometry to evaluate the expression of cdc-ev surface factors that induce blood coagulation, namely tissue factor and phosphatidylserine
The author tested the thrombogenicity (the tendency of substances in contact with blood to produce clots or clots) of CDC-EV using a calibrated thrombus chart
.
They used an adhesion model based on blood flow to evaluate coagulation parameters and simulate the flow of blood on a collagen-expressing surface
Then, they measured the therapeutic effects of CDC-EVs in a rat model of acute traumatic coagulopathy, which is caused by multiple traumas and hemorrhagic shock
.
Here, the authors show that in the ATC rat model, early administration of exosomes can significantly reduce the abnormally elevated levels of lactic acid and creatinine in rats without increasing coagulation
These findings indicate that the early management of cdc-ev has the potential to treat shock and trauma, and supports the development of exosomal-based products for combat casualty care
.
"Although further work is needed to clarify the possible clinical significance of CDC-EVs in the treatment of trauma, these results are undoubtedly a very important first step in the evaluation
The authors point out that “research on the use of cdc-ev in trauma care needs to be considered and expanded beyond the cardioprotective benefits it reports
.
”
Increasing evidence from other pre-clinical studies supports the use of exosomes isolated from heart-derived cells to treat diseases and take advantage of their anti-inflammatory, anti-fibrotic, pro-angiogenic, and anti-apoptotic effects
.
More than 100 peer-reviewed research articles have conducted research on cdc and managed more than 200 human subjects in several clinical trials
Capricor's leading drug candidate, CAP-1002, is a cardiomyocyte therapy that is currently in clinical development as a treatment option for Duchenne muscular dystrophy (DMD) and COVID-19
.
Marbán said: "We believe that the mechanism of action of our leading product CAP-1002 is these exosomes.
We have seen positive clinical data on these cells in multiple studies
.
It is worth noting that we are currently recruiting for Phase II INSPIRE studies.
CAP-1002 treats severe COVID-19 patients
.
Since one of the pathological sequelae of trauma is a hyperimmune response, which is similar to what we have seen in COVID-19 patients, we look forward to sharing the data when INSPIRE becomes available
.
"
